Results October 2019 innovation to impact grants competition

We are pleased to announce the results of the most recent Innovation to Impact Grants competition to support the next phase following a productive Innovation or CBCF research grant, with the goal of working towards or achieving a significant impact on cancer. Below is a listing of newly awarded Innovation to Impact Grants.

Out of a total of 28 grant applications reviewed, 4 Canadian Cancer Society Innovation to Impact Grants have been approved – a 14% success rate. Funds committed to this competition have been made possible by the significant efforts of CCS donors and volunteers across the country. These projects total more than $1.5 million in funding over the full term of these grants.

i2I-20 Abstracts

Program Statistics

Please note:

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is November 1, 2020.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.

Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Alain, Tommy
Children's Hospital of Eastern Ontario
Bioengineering peak transgene production during viral oncolysis
2020/2021 :  $150,000
2021/2022 :  $150,000
2022/2023 :  $150,000
Morin, Gregg
BC Cancer, part of the Provincial Health Services Authority
Clinical application of a targeted proteomic classifier for triple negative breast cancer
2020/2021 :  $149,998
2021/2022 :  $149,988
2022/2023 :  $149,953
Turcotte, Eric
Université de Sherbrooke
Combined 4FMFES and FDG PET imaging in advanced breast cancer: a phase II study
2020/2021 :  $150,000
2021/2022 :  $150,000
2022/2023 :  $149,668
Ursini Siegel, Josie
Jewish General Hospital
Capitalizing on an oxidative stress response to sensitize poor outcome cancers to PARP inhibitors.
2020/2021 :  $58,280
2021/2022 :  $58,280
2022/2023 :  $58,280
Last modified on: June 2, 2020